Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben-Horin

Showing results (351-360 of 362) with videos related to

Pageof 37
Sort By:
Inflammatory Bowel Diseases|February 2, 2012
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of responseLior Katz, Javier P Gisbert, Beth Manoogian, et al.
Alimentary Pharmacology & Therapeutics|June 7, 2018
Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognitionJ Goncalves, M Santos, R Acurcio, et al.
Inflammatory Bowel Diseases|June 8, 2017
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective StudyUri Kopylov, Konstantinos Papamichael, Konstantinos Katsanos, et al.
Alimentary Pharmacology & Therapeutics|May 16, 2020
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapyUri Kopylov, Jurij Hanzel, Claire Liefferinckx, et al.
JCI Insight|June 1, 2023
Mucosal transcriptomics highlight lncRNAs implicated in ulcerative colitis, Crohn's disease, and celiac diseaseTzipi Braun, Katya E Sosnovski, Amnon Amir, et al.
Inflammatory Bowel Diseases|May 23, 2018
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European StudyUri Kopylov, Bram Verstockt, Luc Biedermann, et al.
Journal of Crohn'S & Colitis|July 31, 2025
ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1Torsten Kucharzik, Stuart Taylor, Mariangela Allocca, et al.
Gastroenterology|October 31, 2021
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFαHadar Edelman-Klapper, Eran Zittan, Ariella Bar-Gil Shitrit, et al.
Journal of Crohn'S & Colitis|June 10, 2025
The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched studyUria Shani, Monica State, Radu Bogdan Mateescu, et al.
Vaccines|March 26, 2022
COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli ExperienceLev Lichtenstein, Benjamin Koslowsky, Ami Ben Ya'acov, et al.
Pageof 37

Showing results (351-360 of 362) with videos related to

Sort By:
Pageof 37
Inflammatory Bowel Diseases|February 2, 2012
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of responseLior Katz, Javier P Gisbert, Beth Manoogian, et al.
Alimentary Pharmacology & Therapeutics|June 7, 2018
Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognitionJ Goncalves, M Santos, R Acurcio, et al.
Inflammatory Bowel Diseases|June 8, 2017
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective StudyUri Kopylov, Konstantinos Papamichael, Konstantinos Katsanos, et al.
Alimentary Pharmacology & Therapeutics|May 16, 2020
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapyUri Kopylov, Jurij Hanzel, Claire Liefferinckx, et al.
JCI Insight|June 1, 2023
Mucosal transcriptomics highlight lncRNAs implicated in ulcerative colitis, Crohn's disease, and celiac diseaseTzipi Braun, Katya E Sosnovski, Amnon Amir, et al.
Inflammatory Bowel Diseases|May 23, 2018
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European StudyUri Kopylov, Bram Verstockt, Luc Biedermann, et al.
Journal of Crohn'S & Colitis|July 31, 2025
ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1Torsten Kucharzik, Stuart Taylor, Mariangela Allocca, et al.
Gastroenterology|October 31, 2021
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFαHadar Edelman-Klapper, Eran Zittan, Ariella Bar-Gil Shitrit, et al.
Journal of Crohn'S & Colitis|June 10, 2025
The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched studyUria Shani, Monica State, Radu Bogdan Mateescu, et al.
Vaccines|March 26, 2022
COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli ExperienceLev Lichtenstein, Benjamin Koslowsky, Ami Ben Ya'acov, et al.
Pageof 37